Faizan Iftikhar, MD
Cardiology · McKinney, TXNPI 1417927393
Payments from drug & device makers
Across 876 payments — averaging $2223.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim International GmbH$1M
- Boehringer Ingelheim Pharma GmbH & Co.kg$308K
- American Regent$271K
- Eli Lilly$122K
- Esperion Therapeutics, Inc.$86K
- Astrazeneca UK Limited$33K
- plus $80K from 30 others
Across 2 payments — averaging $49,575 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$99K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim International GmbH | 361 | $1,046,799 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 17 | $308,343 |
| American Regent | 44 | $271,446 |
| Eli Lilly | 16 | $122,204 |
| Esperion Therapeutics, Inc. | 218 | $86,173 |
| Astrazeneca UK Limited | 3 | $33,042 |
| CSL Behring | 20 | $31,797 |
| Bayer | 13 | $17,478 |
| Sanofi US Services Inc. | 1 | $7,500 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $7,383 |
| Novartis | 9 | $6,454 |
| Vifor (international) Ltd. | 2 | $5,500 |
| Merck | 30 | $573 |
| Johnson & Johnson | 23 | $432 |
| AstraZeneca | 15 | $303 |
| Sanofi-aventis U.S. LLC | 17 | $266 |
| Boston Scientific | 12 | $263 |
| Abbott | 10 | $230 |
| Medtronic(2 entities) | 4 | $178 |
| Pfizer | 10 | $158 |
| Amgen | 10 | $158 |
| Scpharmaceuticals Inc. | 7 | $147 |
| Boehringer Ingelheim | 6 | $103 |
| Novo Nordisk | 4 | $91 |
| Regeneron Healthcare Solutions, Inc. | 4 | $87 |
| Siemens Medical Solutions USA, Inc. | 1 | $77 |
| Kowa Pharmaceuticals America, Inc. | 4 | $60 |
| Chiesi USA, Inc. | 2 | $53 |
| Lilly USA, LLC | 2 | $53 |
| Cardiovascular Systems Inc. | 3 | $51 |
| E.r. Squibb & Sons, L.L.C. | 2 | $36 |
| Bridgebio Pharma, Inc. | 1 | $26 |
| Lexicon Pharmaceuticals, Inc. | 1 | $23 |
| Biotronik Inc. | 1 | $17 |
| Philips North America LLC | 1 | $14 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $14 |
How this compares
$1,947,531 in reported general payments places this provider in the 95th percentile of 33 cardiology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other cardiology in McKinney
- Lane MillerCollege Station$37K
- Harvey SluskyWebster$26K
- Shiny MathewkuttyDallas$24K
- Sheikh AhmedHouston$14K
- Ramon TyHouston$11K
- Thieu NguyenHouston$5K
- Nadir AliWebster$3K
- Nadim ZaccaHouston$2K
- Adeniran AriyoDallas$1K
- Ralph NimchanLaredo$702
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.